Localized Delivery of Anti‐CD40/PD‐1 Immunotherapy via a Polymeric Implant is Efficacious, Remodels the Tumor Immune Microenvironment and Improves Safety in a PDAC Mouse Model
Elahe Minaei(University of Wollongong), Kara L. Vine(University of Wollongong), Samantha J. Wade(University of Wollongong), C. Penney(University of Wollongong), Marie Ranson(University of Wollongong), Ronald Sluyter(University of Wollongong), Morteza Aghmesheh(New South Wales Department of Health)
Cited by 1
Related Papers
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
|The Lancet|2018|1.7k
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial
|The Lancet Oncology|2023|663
Towards clinical translation of ligand-functionalized liposomes in targeted cancer therapy: Challenges and opportunities
|Journal of Controlled Release|2018|297
Cytotoxic and Anticancer Activities of Isatin and Its Derivatives: A Comprehensive Review from 2000-2008
|Anti-Cancer Agents in Medicinal Chemistry|2009|269
Biopolymers for Antitumor Implantable Drug Delivery Systems: Recent Advances and Future Outlook
|Advanced Materials|2018|217